

### Use Case



# Network Meta-Analysis

## The Purpose

To conduct a Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) for Indirect Treatment Comparison (ITC).

# About the Client



**INDUSTRY** Big-Pharma





THERAPEUTIC AREA Immuno-oncology

# **Client Requirement**

To conduct indirect treatment comparison from a SLR of published literature by following (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) PRISMA guidelines Checklist and NMA by following Quality of Reporting of Meta-Analyses (QUORUM) checklist.

# The Excelra Approach



Newtwork Meta anaysis/adapted from Cope et al BMC Medicine 2014, 1293

# **Excelra's Contribution**

The results of the comparison are published and communicated through Forest plots, and quality of the studies through Funnel plots.

The NMA model is used for assessing the outcomes of the intervention when head-to-head comparison is not available.

# **Excelra's Value Evidence Service Portfolio**



**Outcomes Research** Value Evidence Communication Epidemiology Modelling



**Economic Modelling** 

**RWE & Big Data Realization** 



SLR & Meta-Analysis

### For more information, visit https://www.excelra.com/value\_evidence/#systematic\_literature



#### About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyze large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients including 15 of the top 20 large Pharma.

marketing@excelra.com

www.excelra.com